

TERCICA INC  
Form 8-K  
May 19, 2005

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington D.C., 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date Of Report (Date Of Earliest Event Reported): 05/18/2005**

**Tercica, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Commission File Number: 000-50461**

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**26-0042539**  
(I.R.S. Employer  
Identification No.)

**651 Gateway Boulevard**  
Suite 950  
South San Francisco, CA 94080  
(Address of Principal Executive Offices, Including Zip Code)

**(650) 624-4900**  
(Registrant's Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
-

## Edgar Filing: TERCICA INC - Form 8-K

Items to be Included in this Report

### Item 8.01. Other Events

In response to an inquiry from us, the U.S. Food and Drug Administration has advised that its Office of Orphan Products Development currently considers that the rhIGF-1:rhIGFBP-3 complex and rhIGF-1 are the same drug for purposes of granting marketing exclusivity under the Orphan Drug Act.

---

#### Signature(s)

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

Tercica, Inc.

Date: May 18, 2005.

By: /s/ Stephen N. Rosenfield

---

Stephen N. Rosenfield  
Senior Vice President of Legal Affairs